OncoMark Ltd are proud to announce the CE marking of the OncoMasTR test.
OncoMark today announced its declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of OncoMasTR, a gene expression profiling test for early-stage breast cancer prognosis.
The OncoMasTR test can determine the probability of recurrence for breast cancer patients, thereby aiding clinicians in determining the best treatment options for their patients and avoiding the costs and severe side-effects from unwarranted chemotherapy, ultimately improving the quality of life of the patient.
“We are delighted to have reached this landmark, having brought the technology from a panel of biomarkers to a clinically validated qPCR test that has the potential to save breast cancer patients unnecessary chemotherapy and healthcare costs. This is due to the dedication and hard work of our Product Development team” said Des O’Leary, CEO of OncoMark.